Trade Curis, Inc. - CRIS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0748 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.2476 |
| Open | 1.2276 |
| 1-Year Change | -91.35% |
| Day's Range | 1.2176 - 1.2976 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 1.2976 | 0.0700 | 5.70% | 1.2276 | 1.2976 | 1.2176 |
| Apr 16, 2025 | 1.2476 | 0.0200 | 1.63% | 1.2276 | 1.2676 | 1.2176 |
| Apr 15, 2025 | 1.1976 | -0.0700 | -5.52% | 1.2676 | 1.2676 | 1.1776 |
| Apr 14, 2025 | 1.2376 | 0.0700 | 6.00% | 1.1676 | 1.2476 | 1.1676 |
| Apr 11, 2025 | 1.1476 | 0.0500 | 4.56% | 1.0976 | 1.1476 | 1.0276 |
| Apr 10, 2025 | 1.1276 | -0.0300 | -2.59% | 1.1576 | 1.1676 | 1.0976 |
| Apr 9, 2025 | 1.1776 | 0.0800 | 7.29% | 1.0976 | 1.1776 | 1.0376 |
| Apr 8, 2025 | 1.1376 | -0.0200 | -1.73% | 1.1576 | 1.1676 | 1.1376 |
| Apr 7, 2025 | 1.0676 | -0.0300 | -2.73% | 1.0976 | 1.1476 | 1.0676 |
| Apr 4, 2025 | 1.1776 | -0.1000 | -7.83% | 1.2776 | 1.2776 | 1.1776 |
| Apr 3, 2025 | 1.3176 | -0.1000 | -7.05% | 1.4176 | 1.4176 | 1.3176 |
| Apr 2, 2025 | 1.4676 | -0.0500 | -3.29% | 1.5176 | 1.5576 | 1.4676 |
| Apr 1, 2025 | 1.3976 | -0.6800 | -32.73% | 2.0776 | 2.0776 | 1.3676 |
| Mar 31, 2025 | 2.0676 | -0.1400 | -6.34% | 2.2076 | 2.2076 | 2.0676 |
| Mar 28, 2025 | 2.2976 | -0.0700 | -2.96% | 2.3676 | 2.3676 | 2.2476 |
| Mar 27, 2025 | 2.3276 | 0.0500 | 2.20% | 2.2776 | 2.4876 | 2.2676 |
| Mar 26, 2025 | 2.3576 | -0.0600 | -2.48% | 2.4176 | 2.5776 | 2.3276 |
| Mar 25, 2025 | 2.4576 | 0.0100 | 0.41% | 2.4476 | 2.5976 | 2.3976 |
| Mar 24, 2025 | 2.5076 | -0.0900 | -3.46% | 2.5976 | 2.6176 | 2.4576 |
| Mar 21, 2025 | 2.6076 | -0.0200 | -0.76% | 2.6276 | 2.6776 | 2.6076 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Curis, Inc. Company profile
About Curis, Inc.
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Curis, Inc. revenues decreased 2% to $10.6M. Net loss increased 52% to $45.4M. Revenues reflect Other revenue decrease of 100% to $1K. Higher net loss reflects Research & development Expenses B/F increase of 50% to $32M (expense), Other General and administrative, increase of 43% to $8M (expense), General and administrative expenses increase of 75% to $3.4M (expense).
Equity composition
Common Stock $.01 Par, 03/11, 125M auth., 77,397,663 issd., less 1,047,707 shs. in tres. @ $891K. Insiders own 2.72%. IPO 12/92, 3M shs. @ $7 by Montgomery Secs. *8/00, Co.merged with Ontogeny & Reprogenesis & chgd. name from Creative Biomolecules, Inc. FY'03&'04 are RES-Acct. Change. Summ. Qs reflects RES.
| Industry: | Biotechnology & Medical Research (NEC) |
128 Spring Street
4 Maguire Road
LEXINGTON
MASSACHUSETTS 02421
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com